Welcome to our dedicated page for Ideaya Biosciences news (Ticker: IDYA), a resource for investors and traders seeking the latest updates and insights on Ideaya Biosciences stock.
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) is a precision medicine oncology company whose news flow is driven by clinical trial milestones, regulatory interactions, strategic collaborations, and corporate updates. The company regularly issues press releases detailing progress across a deep pipeline of targeted small molecules and antibody-drug conjugates (ADCs) for molecularly defined solid tumors.
News related to IDYA often highlights developments in its lead program darovasertib, an oral protein kinase C inhibitor in clinical trials for uveal melanoma. Updates include enrollment milestones, progression-free survival and overall survival data from trials such as OptimUM-01 and OptimUM-02 in metastatic uveal melanoma, and neoadjuvant data from OptimUM-09 and the Phase 3 OptimUM-10 trial in primary uveal melanoma. IDEAYA also reports on regulatory designations for darovasertib and its collaboration with Servier for rights outside the United States.
Investors following IDEAYA news will see frequent announcements on its broader pipeline, including IDE397 for MTAP-deleted urothelial cancer and NSCLC, IDE849 for small cell lung cancer and neuroendocrine carcinomas, IDE161 as a PARG inhibitor for ADC combinations, IDE034 as a bispecific B7H3/PTK7 TOP1 ADC, IDE574 as a KAT6/7 dual inhibitor, and IDE892 as a PRMT5 inhibitor. Press releases cover IND submissions and clearances, Phase 1 and Phase 2 data readouts, and plans for upcoming medical conference presentations.
IDYA news also includes financial results, cash runway commentary, licensing transactions such as the Servier darovasertib agreement, and governance or compensation updates reported via SEC filings and corporate press releases. Tracking this news stream provides insight into IDEAYA’s clinical progress, partnering activity, and evolving precision oncology strategy.
IDEAYA Biosciences, Inc. (Nasdaq: IDYA) has priced an underwritten public offering of 6,666,667 shares of its common stock at $15.00 per share, potentially raising $100 million in gross proceeds. The offering includes an option for underwriters to purchase an additional 1,000,000 shares. Proceeds will support the development of IDE397, IDE196, and other pipeline candidates, as well as general corporate purposes. The offering is scheduled to close around June 22, 2020.
IDEAYA Biosciences, Inc. (Nasdaq:IDYA) announced a proposed public offering of up to $60 million in common stock, with an additional $9 million option for underwriters. Proceeds will fund development of drug candidates including IDE397 and IDE196, along with biomarker research and working capital. The offering is subject to market conditions and will utilize a shelf registration statement previously filed with the SEC. J.P. Morgan, Citigroup, and Jefferies are acting as joint book-running managers.
IDYA has partnered with GlaxoSmithKline (GSK) to advance Synthetic Lethality programs, including MAT2A and Pol Theta. These programs, projected to enter clinical trials in the next three years, utilize innovative approaches to target cancer-specific vulnerabilities. IDEAYA will manage the MAT2A program's early development, covering initial costs, while sharing profits with GSK. The collaboration aims to enhance precision medicine in oncology, focusing on significant solid tumors. Regulatory clearance is required to finalize the partnership.